SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a broader selloff in AI data-center and neocloud stocks, amplified by Elon Musks warning that many operators could fail or consolidate as debt financing tightens. Traders debate whether IRENs customer contracts, infrastructure and AI demand distinguish it from weaker peers, or whether capital needs and execution risks justify further concern.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broader neocloud selloff as traders react to Elon Musks warning about industry consolidation and worries that tighter credit and heavy data-center spending could leave some AI infrastructure underfunded or underutilized. The community is divided: bears see financing and execution risks, while bulls argue Nebius is better positioned than weaker peers and that the sectors demand and contracts remain strong.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid Elon Musks warning that debt-dependent neoclouds face failures and consolidation, amplifying concerns about the companys heavy borrowing, financing access and ability to turn AI demand into returns. Traders are divided between fears of insolvency and dilution and bullish arguments that demand, customer commitments and Nvidias backing could support the business; some also view Musks comments as self-interested.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp selloff and subsequent rebound are driving attention to MSTR as a leveraged proxy for the cryptocurrency. Traders are split between bullish dip-buying and short-squeeze arguments, and bearish concerns about further Bitcoin weakness and Strategys dilution and financing risks.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Traders are focused on a sharp selloff in AI data-center and neocloud stocks after Elon Musk warned that tighter debt markets could leave many operators struggling; concerns about financing, leverage and CoreWeaves exposure add to the pressure. Some see those risks as a broader threat to APLD, while others argue its contracted data-center pipeline, insider purchases and continuing AI demand make it better positioned than smaller operators.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibres latest earnings have sparked debate: strong revenue growth was offset by declining profit and margin compression as the company invests heavily in shipping, logistics, and credit. Some traders view the selloff as an opportunity given the businesss growth, while others worry that profitability is lagging and the stocks expectations remain high.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher is drawing attention amid a steep selloff across AI data-center stocks, with traders pointing to its convertible financing and dilution alongside broader concerns about tighter debt markets and Musks warnings about weaker neocloud operators. Bulls argue CIFRs powered-shell and long-term lease model sets it apart from GPU-heavy neoclouds, while bears focus on financing, execution and selling-pressure risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention after Brazils election resultLulas unexpected win over Flvio Bolsonarosparked a sharp selloff as traders reassessed expectations for a more market-friendly outcome and worried about political and economic uncertainty. The community is split between alarm over the drop and dip-buyers who view the reaction as excessive.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas runoff victory has challenged the Bolsonaro-election trade and raised concerns about political uncertainty and possible pressure on Petrobrass dividends. Traders are split between viewing the selloff as a buying opportunity given the companys low-cost oil production and seeing government intervention as a risk.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs sharp selloff and prolonged run of red sessions dominate discussion, with traders citing weakness across Bitcoin miners, concerns about Bitcoin-linked profitability and financing costs, and frustration that the AI/HPC pivot has yet to produce signed tenant leases. Sentiment is split between expectations of further losses, including around the upcoming earnings report, and dip-buyers who see the stock as oversold and due for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million.
PDS Biotechnology (NASDAQ:PDSB) shares movedread more...

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ 

Equity

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode

Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.

This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

Soon-Shiong $22.3 Million Funding Firepower could Further Fuel PDS Biotech Move

PDS Biotech (NASDAQ:PDSB) is entering a potentially pivotal stretch with fresh capital, a high-profile new board member and a sharply narrowed clinical strategy centered on its PDS0301 immunocytokine.

PDS Biotech Stock Surges Tuesday: What's Driving the Action?

Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.read more...

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million.
DataMEDS AI (NASDAQ:MEDS) shares increased byread more...

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet  

PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.



Stocks Making Noise as the Market Hunts for Its Next Big Winners

The small-cap market is serving up a mix of stories centered on PDS Biotech (NASDAQ:PDSB), NeOnc (NASDAQ:NTHI), CEA Industries (NASDAQ:BNC), Bluejay Diagnostics (NASDAQ:BJDX), NuRAN Wireless (NASDAQ:NUR) and Roivant Sciences (NASDAQ:ROIV).

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> surged 178% Monday to $89.92, its best day on record and highest close since December 2021.</li><li>Kodiak said its separate eye drugs Zenkuda and KSI-501 met the primary endpoints in the Phase 3 Daybreak trial against the active ingredient in original Eylea.</li><li>Jefferies raised its <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> price target to $112, implying about 25% upside from Monday’s close. LifeSci Capital’s $145 target implies 61% upside, while H.C. Wainwright’s $96 target implies 7%.</li></ul>Shares of Kodiak Sciences (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>) broke into September’s top five biotech gainers on a key eye drug win. Still, investor Martin Shkreli questioned whether it can outshine Eylea, Regeneron’s established treatment for wet age-related macular degeneration (AMD).<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> soared 178% on Monday to $89.92, logging its best day on record and closing at its highest level since December 2021. The rally lifted its September gain to 141%, behind only PDS Biotechnology (PDSB), up 258%, and Indaptus Therapeutics (INDP), up 187%, among biotech stocks.&nbsp;With PDSB valued at less than $50 million, Kodiak trailed only Indaptus among biotech companies worth more than $100 million. It outperformed GRAIL (GRAL), up 67% this month; Moderna (MRNA), up 41%; and Iovance Biotherapeutics (IOVA), up 35%.<img src="https://news.stocktwits-cdn.com/kod_biotech_0e2c321288.png" alt="kod biotech.png"><h2 class="st-heading-2">Daybreak Delivers A Double Win For <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> Stock</h2>Kodiak said on Monday that two separate experimental drugs, Zenkuda and KSI-501, met the primary endpoints in its Phase 3 Daybreak trial. Each produced vision gains that were non-inferior to those achieved with 2-milligram Aflibercept, the active ingredient in Regeneron’s (REGN) original Eylea.&nbsp;<img src="https://news.stocktwits-cdn.com/record_rally_kod_da4ae67085.png" alt="record rally kod.png">Zenkuda targets VEGF, a protein involved in the abnormal blood vessel growth seen in wet AMD. Kodiak said that 54% of Zenkuda patients reached a 24-week dosing interval at one year under criteria that called for retreatment when retinal fluid appeared. The company also reported no intraocular inflammation in the Zenkuda arm. It plans to file for approval in the fourth quarter using data from five positive Phase 3 studies across three eye conditions.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kodiak.com/news-releases/news-release-details/zenkuda-and-tabirafusp-ted-meet-primary-endpoints-pivotal?utm_source=chatgpt.com">&nbsp;</a>KSI-501, also called Tabirafusp-ted, is a different drug. It targets both VEGF and IL-6, a protein associated with inflammation. It met Daybreak’s vision endpoint and a key retinal anatomy endpoint. Kodiak plans further analyses to see whether particular wet AMD patients benefit from the added IL-6 targeting, while a separate Phase 3 trial is studying KSI-501 in diabetic macular edema.<h2 class="st-heading-2">Shkreli Pushes Back On Kodiak’s Win&nbsp;</h2>Shkreli&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104520450999284092">congratulated</a> Kodiak on meeting both primary endpoints, but called for the numerical vision results against Eylea and pointed to competition from Eylea biosimilars. He had said last week that he was&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2103521047639171529">short KOD</a> ahead of the readout and predicted that the stock would fall.&nbsp;When another investor praised Zenkuda’s six-month dosing and suggested Kodiak could become a takeover target, Shkreli<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104705935717335382">&nbsp;asked</a>: “How do you know you can't get the same out of Eylea? presumably vastly cheaper”In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104705348976415050">separate post</a>, he said that “the drug still sucks,” called the formulation change “just an extra loading dose” and argued that Zenkuda’s numerical vision result was worse. He had also<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104363503456813292">&nbsp;questioned</a> whether the formulation changes could improve efficacy. Shkreli’s criticism extended to KSI-501. He<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104554538925482159">&nbsp;argued</a> that its IL-6 targeting offered no benefit beyond Zenkuda’s VEGF targeting.&nbsp;The FDA has approved interchangeable biosimilars to original Eylea, adding competition for its 2-milligram formulation. Meanwhile, Regeneron's separate Eylea HD has an approved dosing interval of up to 20 weeks for eligible wet AMD patients.&nbsp;<h2 class="st-heading-2">Wall Street Lifts <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> Targets After Daybreak Win</h2>Analysts responded to Daybreak with steep price target increases. Jefferies raised its Kodiak target to $112 from $56, maintained its ‘Buy’ rating and called the Zenkuda outcome a “slam dunk.” It lifted its estimated probability of success to 80% from 65% and its peak sales forecast to $1.8 billion from $400 million.LifeSci Capital raised its target to $145 from $85 and kept its ‘Outperform’ rating, calling Eylea-like efficacy paired with differentiated durability as a “best-case scenario outcome.” H.C. Wainwright lifted its target to $96 from $58, maintained its ‘Buy’ rating and singled out Zenkuda’s rapid and sustained retinal drying as “highly compelling.”Evercore ISI said that the initial release “reads excellent,” while seeking more detail beyond the topline announcement. Citi said Kodiak’s data raised the longer-term competitive bar for Regeneron, but pointed to Eylea HD’s broad label, physician familiarity, and momentum with patients.Based on <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>’s last close, the revised targets imply 25% upside at Jefferies, 61% at LifeSci Capital and 7% at H.C. Wainwright.<h2 class="st-heading-2">How Do Retail Traders Feel About <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>?</h2>On Stocktwits, retail sentiment for <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> jumped to ‘extremely bullish’ from ‘neutral’ levels a week ago amid ‘extremely high’ message volume. Followers for the ticker have also risen 9% in a year, indicating healthy retail interest in the stock.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/kod_ss_4e2c18a822.png" alt="kod ss.png" width="642" height="370"><figcaption><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> sentiment and message volume as of September 28 | Source: Stocktwits</figcaption></figure>One bullish user&nbsp;<a href="https://stocktwits.com/FetchDog/message/665283498">said</a>, “<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">$KOD</a> My GUESS is an offering at $75 per share to raise $600 million. Probably tomorrow- it takes time to find Daddys with $600 million.”<stembedurl>https://stocktwits.com/FetchDog/message/665283498</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/tahloolaaa/message/665292156">said</a>, “<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">$KOD</a> This is far superior to eyelea and faricimab.&nbsp; Take a look at what those drugs are doing annually.”<stembedurl>https://stocktwits.com/tahloolaaa/message/665292156</stembedurl><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock has surged 222% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-change-of-control-payout-plan-ceo-senior-execs-buyout-buzz/cZMmkiMRBX0">ASTS Stock Rises Overnight: Change-Of-Control Payout Plan For CEO, Senior Execs Fuels Buyout Buzz&nbsp;</a>

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

GRAIL Inc.

iShares Biotechnology ETF

Indaptus Therapeutics Inc

Iovance Biotherapeutics Inc

Kodiak Sciences Inc

Moderna Inc

Regeneron Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.11
Prev Close	$1.16
Open	$1.11
Dividend Yield	0.00%
50-Day Moving Average	$0.6844
Beta	2.18
Avg. Volume	62.36M
PE Ratio	-1.73

52-Week High	$1.79
52-Week Low	$0.1952
Market Capitalization	$116.56M
EPS (Annual)	-$0.7437
Price to Book	-17.34
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PDSB Fundamentals